<DOC>
	<DOCNO>NCT01257815</DOCNO>
	<brief_summary>This study evaluate new investigational treatment regimen three consecutive monthly dos ranibizumab follow as-needed treatment regimen , monthly follow-up first three month two-monthly follow-up 18 month patient visual impairment due diabetic macular oedema.The aim study determine treatment regimen effective safe patient .</brief_summary>
	<brief_title>Ranibizumab Treatment Diabetic Macular Oedema With Bimonthly Monitoring After Phase Initial Treatment</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients Type 1 Type 2 diabetes mellitus . Patients visual impairment due focal diffuse diabetic macular oedema ( DMO ) , cause , least one eye eligible laser treatment opinion investigator . Best Corrected Visual Acuity 78 24 letter study eye use Early Treatment Diabetic Retinopathy Study ( ETDRS ) like grade chart ( approximate Snellen equivalent 20/32 20/320 ) . Increased central retinal thickness , opinion investigator , due DMO . Concomitant condition study eye could prevent improvement visual acuity study treatment . Active intraocular inflammation ( grade trace ) infection either eye enrollment . History uveitis either eye time . Structural damage within 0.5 disc diameter centre macular study eye likely preclude improvement visual acuity follow resolution macular oedema . Planned medical surgical intervention 18month study period . Uncontrolled glaucoma either eye screening . Blood pressure systolic &gt; 160 mmHg diastolic &gt; 100 mmHg screening . Ocular condition study eye require chronic concomitant therapy topical ocular systemically administer corticosteroid . History acute thromboembolic event within 4 month screen . Untreated diabetes mellitus . Evidence advance , severe unstable concomitant disease treatment may interfere evaluation put patient special risk . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Diabetic retinopathy</keyword>
	<keyword>Macular oedema</keyword>
	<keyword>Visual acuity</keyword>
</DOC>